Journal of Dermatology Research and Skin Care

Homeostatic renormalization of hair and skin tissue using adult stem cell S2RM technology

Spring Dermatology & Skin Care Expo Conference
May 14-15, 2018 | Montreal, Canada

Greg Maguire

University of California, USA

Scientific Tracks Abstracts : Dermatol Res Skin Care

Abstract:

Different sets of molecules are released from multiple stem cell types in any given tissue, and are naturally packaged into a “smart liposome” called the exosome, which has highly evolved protection, targeting, and delivery characteristics for the molecules. Most of the healing properties of stem cells derive from these molecules. Chronological aging, and many environmental factors during the aging process, lead to diminished stem cell function throughout our bodies, and the quantity and quality of the stem cell released molecules (SRM) that nourish the hair and skin are reduced, leading to disruption of homeostasis and a chronic para-inflammatory state. This unhealthy state of the skin and hair forms wrinkles, sags, and loss of elasticity, and follicular miniaturization. Homeostatic renormalization can be achieved by returning the normal SRM to the aged skin and scalp, and is best achieved using multiple types of adult stem cells normally found in the particular tissue. The collection of molecules from multiple stem cells types, as opposed to a single molecule traditionally used in therapeutic development is called a “systems therapeutic.” The systems therapeutic induces emergent, collective efficacy that is vastly greater than that of using one or a few molecules, and when developed using endogenous human molecules and exosomes, produces a superior therapeutic with optimal safety and efficacy profiles. Examples of the therapeutic value of S2RM technology for a number of skin (e.g. acne) and hair conditions (e.g. alopecia) will be shown.

Biography:

Greg Maguire is a former Professor of Neuroscience and Ophthalmology at the University of California, San Diego School of Medicine. He was a Fulbright-Fogarty Fellow at the National Institutes of Health USA, and his research has been supported by the NIH and NSF, as well as numerous private foundations. With over 100 publications emanating from his work at UC Berkeley and UCSD, he recently established two biotech companies, where his patentedS2RM technology is used to treat neurodegenerative and skin diseases, and conditions.
Email: madaleneheng@aol.com

PDF HTML